AsianScientist (Feb. 14, 2012) – Quintiles yesterday launched two unique services – Strategic Drug Development and Consulting at Quintiles – to help biopharmaceutical companies navigate the complexities of the Asia market.
Quintiles’ new Strategic Drug Development organization will help biopharma companies design and implement strategies that take into account the Asia product commercialization opportunity and regulatory hurdles.
“Beyond simply helping customers meet their needs in the region, our goals are to help define them,” said Amar Kureishi, Chief Medical Officer and Head of Strategic Drug Development for Quintiles in Asia.
Also launched was Consulting at Quintiles practice in Asia to help customers navigate the New Health by linking business strategy, industry expertise, and data-driven insights.
“Drug development and commercialization in Asia will benefit greatly from new, strategic approaches,” said Christian Gabel, Ph.D., VP and Head of Consulting at Quintiles Asia.
“Quintiles draws on expertise and lessons learned from 30 years of product development and commercialization in the West to bring differentiated approaches to companies in the East,” he said.
——
Source: Quintiles.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
